ArticleLife (Basel, Switzerland)2021
Sarcopenia-The Impact on Physical Capacity of Liver Transplant Patients.
Article in Life (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 5 syntheses or guidelines pooled it, 12 citations in OpenAlex.
- Systematic review of prognostic value of cardiorespiratory fitness in patients with cirrhosis.BMC gastroenterology · 2026Pooled it
- The impact of exercise on improving sarcopenia in patients with liver cirrhosis: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Sarcopenia As a Predictor of Survival and Complications of Patients With Cirrhosis After Liver Transplantation: A Systematic Review and Meta-Analysis.Clinical transplantation · 2025Pooled it
- Prevalence and clinical impact of sarcopenia in liver transplant recipients: A meta-analysis.World journal of gastroenterology · 2024Pooled it
- Correlation between sarcopenia and cirrhosis: a meta-analysis.Frontiers in nutrition · 2023Pooled it
- Type II fibre atrophy and nuclear disruption in decompensated cirrhosis.JHEP reports : innovation in hepatology · 2025Article
- Cognitive Performance in Patients With Alcohol-Associated Liver Disease Undergoing Liver Transplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2025Article
- Radiological assessment of skeletal muscle index and myosteatosis and their impact postoperative outcomes after liver transplantation.Radiology and oncology · 2023Article
- Laboratory Profile of COVID-19 Patients with Hepatitis C-Related Liver Cirrhosis.Journal of clinical medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Optimizing patients' condition before liver transplantation (LT) could potentially improve survival of LT patients. We focused on sarcopenia, as a common factor in liver transplant candidates that can impact their cardiopulmonary performance at the point of listing, morbidity, and mortality after LT. We performed a single-center cohort study on 98 consecutive patients with liver cirrhosis who were transplanted between March 2015 and December 2017. The third lumbar vertebra skeletal muscle index (L3SMI) was calculated using CT imaging to distinguish sarcopenia at listing for LT. Data regarding liver function, body mass index (BMI), cardiac biomarkers, the peak oxygen uptake (VO2) and LT outcome were collected and correlated to L3SMI. For data analysis the Dell Statistica (Version 13. Dell Inc., Rondrock, TX, USA) was used. In total, 98 cirrhotic patients were included. Fifty-five (56.1%) patients, mostly males, had sarcopenia according to L3SMI, with the lowest L3SMI in males with alcohol-related liver disease. Lower L3SMI correlated with lower BMI, lower VO2 peak, and higher NTproBNP (all
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.